Heart failure with preserved ejection fraction determination by exercise ultrasonography follow-up
Completed
- Conditions
- Heart failure with preserved ejection fraction - Diastolic heart failure10019280
- Registration Number
- NL-OMON51990
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 170
Inclusion Criteria
- Participants of the HELPFul study with a baseline diagnosis of LVDD without
clinical signs or symptoms of heart failure (stage B heart failure)
- Participants consenting to be contacted for follow-up studies of the HELPFul
study
- Participants who are able to read and understand the Dutch language.
- Participants who are willing and able to provide written informed consent for
participation in this study.
- Participants who agreed that results of the follow-up measurements are
reported to the treating physician.
Exclusion Criteria
- Participants who received a heart transplantation or left ventricular assist
device (LVAD) in the period between baseline and follow-up.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The deterioration of LVDD towards HFpEF (stage C/D heart failure), measured by<br /><br>(stress) cardiac ultrasonography assessing functional and structural<br /><br>parameters, combined with natriuretic peptide measurements and clinical<br /><br>evaluation. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Paramaters that are collected for exploratory etiological hypothesis generation<br /><br>and further phenotyping of the heterogeneous population of patients with<br /><br>deteriorating diastolic function and HFpEF. Parameters include clinical<br /><br>factors, echocardiography paramaters (such as global longitudinal strain of the<br /><br>left ventricle and the left atrium calculated from standard echocardiography<br /><br>images) and biomarker parameters that can help to explain what individuals in<br /><br>stage B heart failure are at high risk of progression to stage C/D heart<br /><br>failure. Promising blood biomarkers (e.g. omics related to vascular<br /><br>dysfunction) will be measured again, and promising new biomarkers, e.g. BNP<br /><br>measurements after exercise will be added. To further elaborate the cardiorenal<br /><br>syndrome within our cohort urine biomarkers will be measured. </p><br>